Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

alvocidib (DSP-2033)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sumitomo Pharma

Drug class:

CDK9 inhibitor

Related drugs:

CDK1 overexpression	Adrenal Cortex Carcinoma	CDK1 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
CDK2 overexpression	Adrenal Cortex Carcinoma	CDK2 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
MCL1 expression	Acute Myelogenous Leukemia	MCL1 expression	Acute Myelogenous Leukemia	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
MCL1 expression	Myelodysplastic Syndrome	MCL1 expression	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
ZRSR2 mutation	Myelodysplastic Syndrome	ZRSR2 mutation	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
ASXL1 Y588X	Myelodysplastic Syndrome	ASXL1 Y588X	Myelodysplastic Syndrome	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D
MCL1 amplification	Ewing Sarcoma	MCL1 amplification	Ewing Sarcoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D